Departamento de Química e Bioquímica

Sala/Gabinete 8.2.50
Ext. Principal 28250

Carreira Investigação
Categoria Investigador FCT nível junior


Google Scholar

Palavras Chave


Scientific Interests

Dr. Lopes-Pacheco’s research is focused on translational medicine for respiratory diseases with specific aims at: 1) understanding the molecular and cellular mechanisms that lead to dysfunction and/or premature degradation of CFTR mutants, 2) developing novel pharmacological therapies for cystic fibrosis (CF), and 3) investigating cell-based and gene-based therapies for respiratory diseases (ARDS/ALI, asthma, CF, COPD/emphysema, silicosis).

Publicações selecionadas
  • Lopes-Pacheco M. "CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine". Front Pharmacol , 2020; 10: 1662. doi: 10.3389/fphar.2019.01662.
  • Lopes-Pacheco M, Silva IAL, Turner MJ, Carlile GW, Sondo E, Thomas DY, Pedemonte N, Hanrahan JW, Amaral MD. "Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR". Biochem Pharmacol, 2020; 180: 114133. doi: 10.1016/j.bcp.2020.114133.
  • Lopes-Pacheco M, Robba C, Rocco PRM, Pelosi P. "Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome". Cell Biol Toxicol, 2020; 36: 83-102. doi: 10.1007/s10565-019-09493-5.
  • Lopes-Pacheco M, Boinot C, Sabirzhanova I, Rapino D, Cebotaru L. "Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis". Cell Physiol Biochem, 2017; 41: 2194-2210. doi: 10.1159/000475578.
  • Lopes-Pacheco M, Xisto DG, Ornellas FM, Antunes MA, Abreu SC, Rocco PR, Takiya CM, Morales MM. "Repeated administration of bone marrow-derived cells prevents disease progression in experimental silicosis". Cell Physiol Biochem, 2013; 32: 1681-1694. doi: 10.1159/000356603.

Ver todas as Publicações